Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Int J Clin Oncol. 2009 Dec;14(6):518-24. doi: 10.1007/s10147-009-0912-5. Epub 2009 Dec 5.
The aim of this study was to estimate interindividual differences in the antiemetic effects of 5-HT(3) receptor antagonists by evaluating the influence of pharmacokinetics on 5-HT(3) receptor occupancies, based on receptor occupancy theory.
We analyzed interindividual differences of 5-HT(3) receptor occupancies and antiemetic effects after the oral and/or intravenous administration of standard doses of the following 5-HT(3) receptor antagonists: azasetron, granisetron, indisetron, ondansetron, ramosetron, and tropisetron.
The interindividual difference between maximum and minimum 5-HT(3) receptor occupancies after oral administration ranged from 0.6% to 64.0%, and that difference after intravenous administration ranged from 0.6% to 29.6%. Following oral administration, the interindividual difference between maximum and minimum complete vomiting inhibition rates ranged from 0.2% to 16.1%. After intravenous administration, that difference ranged from 0.8% to 52.5%.
Interindividual differences in the clinical effects of 5-HT(3) receptor antagonists could be evaluated based on receptor occupancy theory, and the differences varied among drugs. Drug selection considering these individual variations might be useful for the patients who experienced vomiting associated with chemotherapy.
本研究旨在通过评估药代动力学对 5-HT3 受体占有率的影响,基于受体占有率理论来估计 5-HT3 受体拮抗剂的止吐作用的个体间差异。
我们分析了个体间差异的 5-HT3 受体占有率和止吐作用后,口服和/或静脉给予标准剂量的以下 5-HT3 受体拮抗剂:阿扎司琼、格拉司琼、吲达司琼、昂丹司琼、雷莫司琼和托烷司琼。
口服后最大和最小 5-HT3 受体占有率的个体间差异范围为 0.6%至 64.0%,静脉给药后为 0.6%至 29.6%。口服后,最大和最小完全呕吐抑制率的个体间差异范围为 0.2%至 16.1%。静脉给药后,该差异范围为 0.8%至 52.5%。
可以根据受体占有率理论评估 5-HT3 受体拮抗剂的临床效果的个体间差异,并且差异在药物之间有所不同。考虑这些个体差异的药物选择可能对经历与化疗相关的呕吐的患者有用。